Skip to main content

Advertisement

Table 1 MiRNAs as early diagnostic markers for pancreatic caner

From: Extracellular and intracellular microRNAs in pancreatic cancer: from early diagnosis to reducing chemoresistance

Biomarker Source Sample size Diagnostic utility Ref.
PaC CP Normal Sensitivity Specificity
miR-18a plasma 36   30 N/A N/A [44]
miR-192 serum 70   40 76.00% 55.00% [46]
miR-196a serum 35 15 15 100.00% 75.00% [48]
miR-210 plasma 11   11 N/A N/A [41]
miR-221 plasma 47   30 74.00% 78.00% [45]
miR-1290 serum 41 35 19 N/A N/A [52]
miRNA-192,-194 serum N/A   N/A 84.00% 75.00% [47]
miR-196a,b serum 24 10 10 100.00% 90.00% [50]
miR-200a serum 45 11 32 84.40% 87.50% [42]
miR-200b serum 45 11 32 71.10% 96.90% [42]
miR-148a, −216a,-217,181a/c, −324-5p, −146a,-210,-345,-574 blood 45 38 33 N/A N/A [61]
miR-20a,-21,-24,-25,-99a,-185,-191 serum 95   81 94.00% 93.00% [62]
miR-21, −210, −155, −196a plasma 28   19 64.00% 89.00% [59]
miR-22,-642,-885-5p blood 11   11 91.00% 91.00% [64]
CA 19–9 and miR-27a-3p serum/PBMCs 129 103 60 85.30% 81.60% [66]
CA 19–9 and miR-16,-196a serum/plasma 140 111 68 92.00% 95.60% [67]
CA 19–9 and miR-145, −150, −223, −636 serum/blood 86 7 44 74.00% 96.00% [68]
CA 19–9 and miR-26b, −34a, −22, −126-5p, −145, − 150, − 223, −505, − 636, − 885-5p serum/blood 86 7 44 73.00% 97.00% [68]
  1. CA 19–9 Carbohydrate antigen 19–9, PaC Pancreatic cancer, CP Chronic pancreatitis